Seek .(US:SKLTY) Mei Ri Jing Ji Xin Wen·2025-06-04 02:30Group 1 - The Hong Kong stock market showed positive trends on June 4, with the innovative drug sector experiencing significant gains, including over 15% increase for Innovent Biologics and over 7% for Zai Lab and Tigermed [1] - The Hong Kong innovative drug ETF (159567) recorded a trading volume exceeding 1.1 billion yuan for three consecutive trading days, indicating high market enthusiasm [1] - The cost and speed advantages of Chinese teams in drug development are highlighted, with a 2-3 times cost advantage and approximately 2 times speed advantage compared to traditional methods, achieving comparable performance to U.S. teams using AI [1] Group 2 - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from both AI advancements and the introduction of new healthcare policies [2] - Head innovative drug companies have entered a profitability cycle, with multiple products commercializing and driving rapid revenue growth, supported by the upcoming introduction of a new healthcare payment policy in 2025 [2]